Understand the source comparison
Native Amylin Versus Pramlintide Versus Cagrilintide
Understanding the differences among these three molecules prevents a common error: treating pramlintide data as if it were cagrilintide data. They share a mechanistic family but differ substantially in structure, pharmacokinetics, and the populations in which
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding the differences among these three molecules prevents a common error: treating pramlintide data as if it were cagrilintide data. They share a mechanistic family but differ substantially in structure, pharmacokinetics, and the populations in which they have been studied. Native human amylin is chemically unstable and prone to aggregation, which is why it is unsuitable as a drug in its own form. Pramlintide is a stabilized short-acting analogue used with insulin at mealtimes. Cagrilintide is a long-acting analogue engineered for once-weekly administration and studied for weight management. The table below summarizes the contrasts.
- Origin
- Endogenous beta-cell hormone
- Stabilized synthetic analogue
- Long-acting synthetic analogue (AM833)
- Stability in solution
- Poor; aggregation-prone
- Improved vs native
- Engineered for stability and long duration
- Typical action duration
- Minutes (physiological)
- Short-acting; per-meal dosing
- Long-acting; once-weekly in trials
- Primary studied use
- Not a drug
- Adjunct to insulin in diabetes (approved)
- Weight management (investigational)
- Prediabetes-specific outcome trials
- Not applicable
- Not the primary focus
- None to date
- Throughout this article, where pramlintide evidence is invoked, it is used only to illustrate that the amylin mechanism can measurably affect gastric emptying, glucagon, and postprandial glucose. It is not offered as evidence about cagrilintide’s specific effects, and it is certainly not evidence about prediabetes prevention.